phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
04 nov. 2024 08h00 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 08h00 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
06 déc. 2023 08h00 HE | Phathom Pharmaceuticals
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
09 nov. 2023 08h00 HE | Phathom Pharmaceuticals
VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
04 juin 2023 21h00 HE | Bragar Eagel & Squire
NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals,...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
30 mai 2023 11h42 HE | The Rosen Law Firm PA
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom...
BES_Mark.jpg
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
26 mai 2023 21h00 HE | Bragar Eagel & Squire
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals,...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
12 avr. 2023 08h00 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
11 avr. 2023 14h39 HE | The Rosen Law Firm PA
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
04 avr. 2023 17h15 HE | The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...